Landon Chan

Clinical Oncologist in Hong Kong

[Andrew Moon @AndrewMMoon]

So thrilled to see our collaborative publication with @tedradonc, @ma5RN and many others now online in @JCO_ASCO

These data from a large, multinational cohort provide further support for EBRT's role in the management of HCC.

https://t.co/dJI1SdMwnK

[Landon Chan @LandonLChan]

@NiuSanford @OncoAlert The optimal dose and fractionation for HCC still confuses to me. Sometimes it is hard to get the dose high with a 5 fraction regimen (eg 40Gy/5) due to OAR but a higher BED can be achieved with a 10 fraction regimen (eg 52.5Gy/10). In that case should we go for 10 fraction…?

[ESTRO @ESTRO_RT]

📢New from EORTC-ESTRO OligoCare in
@TheLancetOncol: this 3rd #OligoCare consensus paper recommends preferred primary endpoints for trials of metastasis directed therapies in #oligometastatic cancer, supporting more patient centred & comparable research.
👉https://t.co/pAfxKXHDSb

[Herbert Loong, MBBS, FASCO @herbloong]

@mollylisc and I are looking forward to hosting Conversations In Thoracic Oncology 2026 (#CITO26) 🫁 at @CUHK_MC in 2+ weeks' time in #HongKong!

Welcoming speakers who are #RisingStars 🌟 in #ThoracicOncology from #HongKong 🇭🇰, #Japan 🇯🇵, #Taiwan 🇹🇼, #ChineseMainland 🇨🇳, #Singapore 🇸🇬 and #SouthKorea 🇰🇷.

@stephanieplsaw @DrYujiUehara @TonyMok9 amongst many others!

@apoddc @APCLC_2023 #drugdevelopment @IASLC

[Arndt Vogel @ArndtVogel]

Clinical guideline for the diagnosis and treatment of fibrolamellar carcinoma
@HEP_Journal
https://t.co/jm0cOxRL0o
👏Timely guideline
👉still very difficult to treat tumor
@ASCO @myESMO @EASLnews @ILCAnews

[Dr. Nina Niu Sanford @NiuSanford]

Happy to share this interactive contouring tutorial for dose-escalated RT in locally advanced pancreas ca, which follows our NRG consensus contouring atlas.

Thank you @johnroubil, @dsouzl, @aiims2738, & the @eContourRadOnc team for working on this case!

https://t.co/oxR785IKAD

[Dr. Nina Niu Sanford @NiuSanford]

Link to contouring atlas:

https://t.co/9S4UAVgrEF

[Dr. Nina Niu Sanford @NiuSanford]

Like PROSPECT, the RT arm in CONVERT received less chemo. Not only was planned # of cycles less (6 v 8), but ~25% never received ANY multiagent chemo.

Hence trial compensates for RT omission by delivering more chemo. In that light, similar DFS/OS (even w N2) actually remarkable.

[Landon Chan @LandonLChan]

Happy to share our review article on Recent advancements for RT in HCC is now online in ESMO Gastrointestinal Oncology!😃
Emerging indications for RT include bridging to transplant, combining with systemic therapy, and its use in oligo-met/PD cases!

https://t.co/5nNLuBjUKq

[Landon Chan @LandonLChan]

@OscarTahuahua Thank you for highlighting our article!

[Oscar Tahuahua @OscarTahuahua]

Recent advancements in radiotherapy for hepatocellular carcinoma

For years, RT played only a limited role in HCC management.

Today, SBRT can achieve >90% 2 year local control with RILD <5% (Radiation-Induced Liver Disease)

Proton therapy reports ~88% 3-year local control with low hepatic toxicity.

Not universally adopted, but difficult to ignore with modern data.
https://t.co/u7ZLsWy9cK @OncoAlert

[Lung Cancers Today @Lung_Cancers]

🫁 Catching up on #ASCO25 news?

⭐ Don't miss this insightful interview with @mollylisc on the LC-SHIELD study, which is evaluating AI-based lung cancer screening in people who have never smoked but are at a high risk for lung cancer.

➡️ Watch: https://t.co/J1EggLodGS

#lcsm

[Therapeutic Advances in Medical Oncology @TAMedOncol]

Checkpoint inhibitors are now standard in advanced HCC, but resistance is common. This review explores how TACE, radiation, and novel combos (triplets, bispecifics, vaccines) may expand efficacy and indications.

Read here: https://t.co/VTCPAkWcay

[Herbert Loong, MBBS, FASCO @herbloong]

We are thrilled to have our new #Dean of @CUHKMedicine @pwychiu visit our small (but very productive! 🤗) Department of #ClinicalOncology @CUHKofficial to discuss future strategic directions and plans. @TonyMok9 #AnthonyChan #WinnieYeo #BrigetteMa #StephenChan @mollylisc @LandonLChan #KelvinYan

[Landon Chan @LandonLChan]

@changhoon_yoo @StephenLChan1 Learning from the giants 🙏🏻🙏🏻🙏🏻 more work to come 🙂

[Landon Chan @LandonLChan]

Happy to share our team’s work published on JHep! This is the first prospective trial testing cabozantinib in the post-IO setting for HCC. Hope this will provide a new standard and benchmark for future trials!
@StephenLChan1 @changhoon_yoo Dr CJ Kyung

https://t.co/8Fh5y12aBL

[Ghassan Abou-Alfa @GABOUALFA]

Congratulations @CUHKofficial Landon Chan, and thank you to all colleagues from Zhongshan Shanghai @NUSingapore Zhongshan Xiamen for joining the quarterly @MSKCancerCenter @MSK_DeptOfMed East West #Liver #HCC Rounds

[Landon Chan @LandonLChan]

@GABOUALFA @CUHKofficial @NUSingapore @MSKCancerCenter @MSK_DeptOfMed @EileenMOReilly @HardingJJMD @Layalmahmasani Thank you for the opportunity and participation in this excellent discussion @GABOUALFA!

[Maria Reig @ma5RN]

Great experience and amazing interaction between participant’s &amp; faculties from👉

🇵🇭🇧🇩🇮🇳🇭🇰🇹🇼🇻🇳🇳🇵🇮🇩🇵🇰🇺🇿🇲🇾🇲🇲🇯🇵🇲🇳 &amp; 🇹🇼 🇩🇪🇯🇵🇸🇬🇬🇧 (🇪🇸🇨🇦+/- 🇦🇷)

Take Home Message
👌 multidisciplinar approach is key
👉 The 🧰 of the #BCLC2022 reflects the Tumor Board Decision
🔝New era #IO &amp; #LRT

[Arndt Vogel @ArndtVogel]

Heading✈️home from Singapore
Many🙏 to ESMO to organize this great advanced course on HCC
👏Excellent lecturers & speakers
👍great discussions with esteemed colleagues from all over ASIA
👉Lots of opportunities but also many inequalities and challenges in access to effective medicines in HCC
@myESMO